Oncolytics Biotech: The oncolytic virus renaissance: improving the efficacy of current immunotherapies

The oncolytic virus renaissance: improving the efficacy of current immunotherapies
Oncolytics Biotech Inc. featured in the pharmphorum’s Deep Dive on Oncology

Pharma companies are turning to oncolytic viruses to increase the chances that patients will respond to immunotherapies such as Merck & Co’s Keytruda. Matt Coffey, CEO of Oncolytics Biotech spoke to pharmaphorum at ASCO: “As a therapeutic area we are having a lot of progress and [oncolytic viruses] are emerging as the standard back bone for check point inhibitor therapy. We have a huge opportunity in breast cancer. We are looking for a partner so we can quickly get through the phase III programme.”

Read More

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...

GET IN TOUCH